Enliven Therapeutics Stock (NASDAQ:ELVN)
Previous Close
$22.65
52W Range
$13.30 - $29.79
50D Avg
$20.36
200D Avg
$20.16
Market Cap
$1.42B
Avg Vol (3M)
$482.48K
Beta
1.02
Div Yield
-
ELVN Company Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.